What is Immunome's net investment in lease?

Immunome (IMNM) reported net investment in lease of $2.83M in Q1 2026.

How has Immunome's net investment in lease changed year-over-year?

Immunome's net investment in lease decreased by 32.1% year-over-year, from $4.16M to $2.83M.

What is the long-term trend for Immunome's net investment in lease?

Over 4 years (2021 to 2025), Immunome's net investment in lease has grown at a 56.2% compound annual growth rate (CAGR), from $500K to $2.98M.

Immunome IMNM Net Investment in Lease

Net Investment in Lease at other companies

Nuvation BioNUVB

——

SELLAS Life Sciences Group, Inc.SLS

——

ArriVent BioPharma, Inc.AVBP

——

IDEAYA Biosciences, Inc.IDYA

——

Summit TherapeuticsSMMT

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's net investment in lease?: Immunome (IMNM) reported net investment in lease of $2.83M in Q1 2026.
How has Immunome's net investment in lease changed year-over-year?: Immunome's net investment in lease decreased by 32.1% year-over-year, from $4.16M to $2.83M.
What is the long-term trend for Immunome's net investment in lease?: Over 4 years (2021 to 2025), Immunome's net investment in lease has grown at a 56.2% compound annual growth rate (CAGR), from $500K to $2.98M.